Advertisement

Topics

FDA approves liposome-encapsulated daunorubicin-cytarabine for poor prognosis AML

06:34 EDT 4 Aug 2017 | ecancermedicalscience

The U.S. Food and Drug Administration has granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS, Jazz Pharmaceuticals, Inc.) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or...

Original Article: FDA approves liposome-encapsulated daunorubicin-cytarabine for poor prognosis AML

NEXT ARTICLE

More From BioPortfolio on "FDA approves liposome-encapsulated daunorubicin-cytarabine for poor prognosis AML"

Quick Search
Advertisement